Knight Therapeutics Inc. Registered Shares o.N.
- BID
6
- ASK
6.05
- 755 Units741 Units
- 07/23, 08:18:50 AM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
65.78%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.03 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 6 G | 0 Units |
| PRICE DETERMINATION TIME | 07/23/2026 / 08:18:50 AM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 6 | 5.9 |
| PREV. DAY'S PRICE | 6.05 | (07/22) |
| CHANGE DAY BEFORE | -0.05 | -0.83 % |
| 52 WEEK HIGH / LOW | 6.25 (07/09) | 3.44 (10/17) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.11 | 0.03 | -0.03 | 0.11 | 0.14 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | 124.48 | - | 58.65 | 45.32 |
PRICE - BOOK RATIO | 0.70 | 0.67 | 0.78 | - | - |
PRICE - SALES RATIO | 1.70 | 1.46 | 1.34 | - | - |
PRICE - CASH FLOW RATIO | 19.57 | 12.50 | 8.57 | - | - |
Master Data
| WKN | A1XE7A |
| ISIN | CA4990531069 |
| SYMBOL | 04K |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | KNIGHT THERAPEUTICS |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 1.64 % | 9.73 % | 34.78 % | 73.18 % | 65.78 % | - | - | 67.57 % |
| HIGH | 6.20 | 6.25 | 6.25 | 6.25 | 6.25 | - | - | 6.25 |
| LOW | 5.90 | 5.60 | 4.50 | 3.46 | 3.44 | - | - | 3.46 |
Dividende
pro Aktie
KNIGHT THERAPEUTICS does not deliver dividend information
Company profile
Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The firm also focuses on building a portfolio of innovative products through in-licensing or acquiring product rights. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montréal, Canada.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.